Alcon AG Q3 FY2026 earnings call

• Financial Performance & Guidance Maintenance:
  • Delivered third-quarter sales of $2.7 billion, up 5% YoY, with year-to-date growth at 6%.
  • Maintained full-year guidance for approximately 6% sales growth and double-digit core EPS growth, despite competitive headwinds.
  • Core diluted EPS rose 15% to $0.91; core gross margin expanded 280 basis points to 65.7%, largely due to tariff refunds.
• Innovation & Product Launches:
  • Implantables: Vivity Pro received FDA approval in early November, with a full U.S. launch planned for January. True Plus is now broadly available in the U.S. Europe has returned to growth following the Panoptix Pro launch.
  • Equipment: Unity VCS and CS drove double-digit growth. Unity is installed in 40% of U.S. teaching hospitals. Next-generation devices (Unity M, Unity DX) are slated for future launches.
  • Vision Care: Triptir reached ~6% market share with >66% commercial coverage. Sustain delivered double-digit growth. Brightly (redness reliever) received FDA approval and will launch in Q1 2027.
• Strategic Acquisition (Neurotech Pharmaceuticals):
  • Acquired Neurotech to add Inselto (CELTO), the first FDA-approved treatment for macular telangiectasia.
  • Expected peak sales of $250–$400 million; anticipated to contribute 75–100 basis points to top-line growth in 2027.
• Market Dynamics & Premiumization:
  • Aggregate eye-care markets grew ~3% in Q3. The contact lens market remains healthy (~4–5% globally), driven by premiumization toward daily disposables and specialty lenses.
  • Advanced Technology IOL (ATIOL) penetration in the U.S. reached 21.9% (+160 bps YoY).
  • Competitive intensity in U.S. implantables is high, with significant trialing/sampling activity expected through early next year.
• Operational Efficiency & Capital Allocation:
  • Restructuring efforts are underway to improve operational efficiency.
  • Generated >$1.3 billion in free cash flow YTD; returned $748 million to shareholders via dividends and buybacks.
  • Efficiency programs are expected to yield ~$130 million in run-rate savings, with the majority hitting in 2027.

• Surgical Franchise: Sales of $1.5 billion, up 4% year-over-year (YoY). This segment represents approximately 55.6% of total revenue.
  • Implantables: Sales of $422 million, down 2% YoY. IOLs were down 1%, offset by a 9% growth in the Panoptix family. Competitive pressure in the U.S. premium IOL market and reimbursement challenges impacted performance.
  • Consumables: Sales of $789 million, up 6% YoY, driven by procedural volumes, price increases, and Valeta adoption.
  • Equipment: Sales of $269 million, up 11% YoY, driven by momentum from the Unity platform and the Valta launch.
• Vision Care Franchise: Sales of $1.2 billion, up 6% YoY. This segment represents approximately 44.4% of total revenue.
  • Contact Lenses: Sales of $737 million, up 5% YoY. Growth was driven by premium trade-up, share gains, and price increases, partially offset by legacy product declines.
  • Ocular Health: Sales of $500 million, up 8% YoY. Sustain grew double digits, supported by share gains and preservative-free formulations, while contact lens care remained soft.

• Full-Year 2026: Maintained guidance for approximately 6% sales growth (consistent with original midpoint). Narrowed expected core operating margin expansion to 100–150 basis points and core diluted EPS growth to 12–14%.
• Key Assumptions: Assumes aggregate eye-care markets grow ~3% for the year; exchange rates hold through year-end; current tariffs (including U.S. import tariffs of 10–12.5%) remain in effect.
• 2027 Outlook (Non-Guidance):
  • Expects above-market sales growth, driven by new IOL launches (Vivity Pro, True Plus), equipment mix shifts (CS vs. VCS), and contribution from Neurotech (75–100 bps).
  • Anticipates 150–200 basis points of underlying operating leverage, though net expansion may be lower due to non-recurring 2026 tailwinds (tariff refunds) and near-term inflation/acquisition pressures.
  • Formal financial guidance for 2027 will be issued in February alongside budget finalization.

• Competitive Pressure in Implantables: Significant competitive trialing and sampling of IOLs in the U.S. premium category are impacting market share and creating headwinds for ATIOL penetration.
• Reimbursement Challenges: Ongoing difficulties with reimbursement for dual procedures and glaucoma implants in the U.S., as well as slower Medicare adoption for Triptir.
• International Market Headwinds: Pricing pressure in Europe’s contact lens market due to online channels and private label brands; slower equipment replacement cycles in specific markets like Japan.
• Regulatory & Execution Risk: Success of the Neurotech acquisition depends on patient identification rates and surgical center readiness for a novel cell therapy procedure.
• Tariff Uncertainty: Exposure to ongoing U.S. import tariffs which impact margins, although recent refunds provided temporary relief.

Q: Analyst asked if Unity unit placements would see a step-up in 2027 and if Brightly would generate stocking orders in Q4. / A: CEO stated unit placements would be similar to 2026, but with a shift toward the larger CS market rather than VCS. Regarding Brightly, no Q4 shipments are expected as retail orders will ship in 2027.

Q: Analyst sought clarity on whether the 150-200 bps of 2027 operating leverage was gross or net of headwinds, and details on implantable share loss. / A: CFO clarified the 150-200 bps is a gross number before subtracting pressures from non-recurring 2026 items (tariff refunds) and inflation. CEO noted global implantable volumes were flat, with share loss concentrated in U.S. ATIO/monofocal segments, but expressed confidence in recovery via Vivity Pro.

Q: Analyst questioned the revenue growth trajectory for equipment given the mix shift from higher-ASP VCS to CS, and requested disaggregation of Valeda’s contribution. / A: CEO corrected that while unit growth may be similar, value growth will be greater due to the larger CS market size. He declined to break out Valeda’s specific contribution but emphasized strong category growth.

Q: Analyst asked about the net impact of Neurotech on 2027 revenue/margins and the ramp-up logic for peak sales. / A: CFO confirmed adding 75-100 bps to total Alcon revenue. CEO explained peak sales ($250-400M) depend on identifying patients and getting them to specialized surgeons, noting the logistics of this rare disease are the key variable.

Q: Analyst inquired about the sustainability of contact lens price increases internationally versus the US, and the relevance of long-term guidance. / A: CEO noted US price sustainability is stronger due to independent OD dominance, while international pricing is pressured by online/private labels. He acknowledged long-term guidance (6-8%) is currently at the low end but believes new white-space products will help drive growth beyond the modest market rate.